Algert Global LLC Tg Therapeutics, Inc. Transaction History

Algert Global LLC

$3.72 Billion
Q3 2024

A detailed history of Algert Global LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Algert Global LLC holds 104,252 shares of TGTX stock, worth $3.5 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

104,252

Previous 147,218 29.19%

Holding current value

$3.5 Million

Previous $2.62 Million 6.91%

% of portfolio

0.07%

Previous 0.09%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$17.21 - $25.28 $739,444 - $1.09 Million	-42,966 Reduced 29.19%	104,252 $2.44 Million
Q2 2024 Aug 14, 2024	BUY	$13.32 - $19.19 $1.29 Million - $1.86 Million	97,118 Added 193.85%	147,218 $2.62 Million
Q1 2024 May 14, 2024	SELL	$13.02 - $21.3 $12,629 - $20,661	-970 Reduced 1.9%	50,100 $762,000
Q4 2023 Feb 14, 2024	SELL	$6.68 - $18.81 $37,341 - $105,147	-5,590 Reduced 9.87%	51,070 $872,000
Q3 2023 Nov 13, 2023	SELL	$8.36 - $26.5 $361,745 - $1.15 Million	-43,271 Reduced 43.3%	56,660 $474,000
Q2 2023 Aug 14, 2023	BUY	$15.48 - $35.0 $980,673 - $2.22 Million	63,351 Added 173.18%	99,931 $2.48 Million
Q1 2023 May 12, 2023	SELL	$10.23 - $19.34 $1.54 Million - $2.91 Million	-150,449 Reduced 80.44%	36,580 $550,000
Q4 2022 Feb 13, 2023	BUY	$5.01 - $11.83 $394,387 - $931,257	78,720 Added 72.68%	187,029 $2.21 Million
Q3 2022 Nov 15, 2022	BUY	$4.57 - $8.4 $39,480 - $72,567	8,639 Added 8.67%	108,309 $641,000
Q2 2022 Aug 15, 2022	BUY	$3.74 - $10.66 $372,765 - $1.06 Million	99,670 New	99,670 $424,000
Q1 2021 May 14, 2021	SELL	$41.61 - $54.3 $507,974 - $662,894	-12,208 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$25.27 - $54.9 $308,496 - $670,219	12,208 New	12,208 $635,000

Others Institutions Holding TGTX

# of Institutions

339

Shares Held

88.5M

Call Options Held

2.35M

Put Options Held

1.7M

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.88B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.

Account

Algert Global LLC Tg Therapeutics, Inc. Transaction History